Trial Profile
The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2023 Status changed from active, no longer recruiting to completed.
- 17 Jul 2023 Planned End Date changed from 30 May 2023 to 20 Aug 2023.
- 17 Jul 2023 Planned primary completion date changed from 30 May 2023 to 20 Aug 2023.